ZIF Polymorphs for Nucleic Acid Delivery and Targeted Knockdown of Gene Expression in Prostate Cancer

06 February 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


Prostate cancer (PC) is the second leading cause of male cancer deaths, the advanced form of which continues to be incurable; and nature of the disease being such that it is highly suitable for gene therapy. However, therapy is hampered by lack of appropriate gene delivery agents available. Recently, metal-organic-framework (MOF) biocomposites have seen increasing applications in DNA technologies, including gene delivery. In this work, a polymorph of zeolitic imidazolate framework-8 (ZIF-8) MOF nanoparticles called ZIF-C are used as gene delivery agents to cause knockdown (KD) of a protein overexpressed by the gene ribosomal protein SA in PC. Feasibility of ZIF-C mediated KD at cytoplasmic levels in PC is demonstrated by RNA interference, whereby RPSA specific siRNA is delivered using ZIF-C. Feasibility of ZIF-C mediated KD at genomic levels is demonstrated by CRISPR/Cas9, whereby RPSA specific CRISPR/Cas9 plasmids are delivered using ZIF-C. Specific targeting is further achieved by coating of ZIF-C with epigallocatechin-gallate (EGCG). Cellular transfection assays reveal the gradual expression of ZIF-C delivered RPSA-targeting nucleic acids for up to 96 hours. Quantitative polymerase chain reactions and genomic cleavage detection demonstrate gradual KD, with ~20% reduction in RPSA expression that is almost doubled to ~40% on EGCG-mediated targeted cellular uptake.


metal organic frameworks
non-viral delivery
gene editing


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.